A trial might have a completion date of 2018, but data will come out across the timeline of the trial. Usually its something like 3, 6 or 9 month data.
although the fact is "CELG" may go down a few more $$, it is in my opinion that starting a position at this level is very prudent. My own proven success strategy that I have established for myself buying quality stocks at all times especially if they are showing some weakness is not buying all at once. Meaning if u considering
investing in CELG and are planning to buy per say "500" shares, your initially purchase should be just 175-200 shares.....then if it goes lower $3-5 u buy your next bet....175-200 shares and finally u will purchase your final trade if it for whatever reason goes lower another $3-5. U can not predict the bottom but doing it this way has put me on a very comfortable position on stocks and have provided me with over 90% profitable trades. CELG and GILD are solid companies with lots of cash, starting a position at this level it is EXTREMELY PRUDENT
regardless of the all the noise being made by the know it all message board members currently participating on this board....do your own DD and invest based on your own analysis not based on some nonsense message board recommendation
Sentiment: Strong Buy
Agree, it's all talk to get votes. Trump is looking for ways to free up markets, and would go with a recommendation by a group of experts, which means nothing will happen. Hillary will do some token gesture or nothing.
Neither Trump nor Hillary will get the necessary support to pass any sort of harmful law even if they wanted to try. The most they will do is to try to cap further price increases to a reasonable percentage. Even if revenue gets cut in half most big cap biotechs will still be cheaper than most utility companies which is insane. Plus if they get forced to cut prices they will lay off people, cut costs and find synergies and growth through acquisitions. CELG trades at about 15 times current year EPS which is less than the S&P but it offers unparalleled growth for this valuation. It is so oversold that it has to bounce soon. I think it is perfectly fine to buy it at these levels with a put to protect from further downside.
Sentiment: Strong Buy
I wouldn't know about that but, this Co. is not going away,
CELG is worth something! We gotta be gettin' close to it
even if it's 80's. So be it. Get it over with.
Who am I calling names? I've made no specific reference to anyone on this board ...only those who these people hope to sell their shares to at higher prices.
Hey Bio - My DD tells me that the only Phase 3 clinical trial for Ozanimod (Oral RPC1063) is for relapsing MS isn't expected to to have an "Estimated Primary Completion Date" until June 2020.
There are also two Phase 3 trials, both of which are currently in the recruiting stage for UC,
One is due to be completed in Sept of 2018 and the other is to be completed in Sept in 2020.
So......... which Ozanimod Phase 3 trial are you referring to that will be coming in 2017??
Please help me clear up my confusion, please!! TIA
We shouldn’t have to choose between using new medicines and keeping costs down. Thanks to many decades of advances in therapies, someone diagnosed with cancer today now has a 67 percent chance of living five years or longer. With the promise of immunotherapies and cancer moonshot efforts, a sense of optimism that we can defeat cancer is growing.
With cures on the horizon, now is the time to invest in preparing the health care system for the economic impact. While reimbursement strategies currently focus on costs and benefits of a treatment in the short-term, a year or two, we will need a long-term view to realize the true benefits of medical advances.
“We grossly underinvest in disease prevention and cures,” Dana Goldman, director of University of Southern California’s Schaeffer Center for Health Policy and Economics, said. “When viewed through a long-term lens, these treatments may be well worth the money, but people are focused on the cost per pill, which is hardly the right metric.”
One of the issues with CELG is pro forma vs gaap. The difference between the two is getting larger and larger from CELG and they need to get that under control. Yes pro forma is 17x earnings, but gaap is at 50x and many look at gaap since that is, in the opinion of many, the better stat.
So yes, pro forma CELG looks like it is being given away, but gaap CELG looks expensive.
I am taking big losses from my Nov '15 purchase, but I am not on margin so can be patient.
Can't really say that 18 major clinical read outs is info that can
not be ignored when forecasting future prospects with large biotech
Sure the clinical trials must turn out positive, but at least CELG has
several opportunities to meaningfully advance its pipeline forward
in the next several quarters
Your brief reply implies to me that you don't believe that CELG
will resent significant trails data in the future.......that I would
strongly disagree with.
This markets is in a huge value bubble right now. The fear level since the beginning of the correction last August continues. People are paying more then 18x next years earnings for Utilities and 20x next years earnings for consumer staples. Its a sad day when a utility like SO trades at 18x forward earnings vs CELG at 13.8x lol. These are the perfect times when long term investors, who are willing to endure some short term pain, can get huge long term gains. I did this same thing back in the spring of 2014 when biotech had a big correction and caught nearly a double off that bottom. 2017 will be the year for biotech. We have Phase 3 data from Ozanimod coming next year. We could see a PDUFA date in 2018. That's 3B or more in sales. That will take us to $150. That doesn't include other data from Mongersen in Chrone's disease.
interesting idea but I doubt the true predictability of negative comments on a Yahoo Finance